| Schedule of non-controlling interests in consolidated entities |
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the six months ended |
|
|
|
|
|
|
|
|
As of June 30, 2020 |
|
June 30, 2020 |
|
As of June 30, 2020 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Aevitas |
|
$ |
(2,155) |
|
$ |
(386) |
|
$ |
(2,541) |
|
37.7 |
% |
Avenue 2 |
|
|
5,584 |
|
|
(2,412) |
|
|
3,172 |
|
77.3 |
% |
Baergic |
|
|
(1,338) |
|
|
(4) |
|
|
(1,342) |
|
34.8 |
% |
Cellvation |
|
|
(1,035) |
|
|
(80) |
|
|
(1,115) |
|
22.5 |
% |
Checkpoint 1 |
|
|
17,334 |
|
|
(5,812) |
|
|
11,522 |
|
76.9 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(943) |
|
|
(282) |
|
|
(1,225) |
|
20.8 |
% |
Helocyte |
|
|
(4,794) |
|
|
(207) |
|
|
(5,001) |
|
18.8 |
% |
JMC |
|
|
120 |
|
|
254 |
|
|
374 |
|
6.9 |
% |
Mustang 2 |
|
|
71,410 |
|
|
(17,740) |
|
|
53,670 |
|
75.6 |
% |
Oncogenuity |
|
|
(14) |
|
|
(156) |
|
|
(170) |
|
25.0 |
% |
Tamid |
|
|
(651) |
|
|
(22) |
|
|
(673) |
|
22.8 |
% |
Total |
|
$ |
83,228 |
|
$ |
(26,847) |
|
$ |
56,381 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended |
|
|
|
|
|
|
|
|
As of December 31, 2019 |
|
December 31, 2019 |
|
As of December 31, 2019 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Aevitas |
|
$ |
(1,249) |
|
$ |
(694) |
|
$ |
(1,943) |
|
35.8 |
% |
Avenue 2 |
|
|
24,269 |
|
|
(19,011) |
|
|
5,258 |
|
77.3 |
% |
Baergic |
|
|
23 |
|
|
(1,162) |
|
|
(1,139) |
|
33.0 |
% |
Cellvation |
|
|
(732) |
|
|
(158) |
|
|
(890) |
|
20.6 |
% |
Checkpoint 1 |
|
|
29,389 |
|
|
(14,687) |
|
|
14,702 |
|
78.0 |
% |
Coronado SO |
|
|
(290) |
|
|
- |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(320) |
|
|
(99) |
|
|
(419) |
|
10.6 |
% |
Helocyte |
|
|
(4,322) |
|
|
(402) |
|
|
(4,724) |
|
19.3 |
% |
JMC |
|
|
(211) |
|
|
325 |
|
|
114 |
|
6.9 |
% |
Mustang 2 |
|
|
62,025 |
|
|
(25,727) |
|
|
36,298 |
|
70.3 |
% |
Tamid |
|
|
(565) |
|
|
(85) |
|
|
(650) |
|
22.8 |
% |
Total |
|
$ |
108,017 |
|
$ |
(61,700) |
|
$ |
46,317 |
|
|
|
Note 1: |
Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. |
Note 2: |
Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights. |
|